Abstract
Tumor-targeted antibody-cytokine fusion proteins, called immunocytokines, are expected to be a useful platform for the development of effective antitumor therapeutic agents; however, their design and cost-efficient production remain as challenges. In this study, we constructed an antibody-cytokine fusion protein (Ia1-TNFα) comprising the single-domain antibody Ia1, which targets epidermal growth factor receptor (EGFR) overexpressed in epithelial tumors and a tumor necrosis factor α (TNFα) domain, which has antitumor activity. Ia1-TNFα was produced in a soluble form by using an Escherichia coli expression system, and after affinity purification of the culture supernatant, an yield of ∼2 mg/L of cell culture was obtained. Gel filtration analysis showed that Ia1-TNFα existed predominantly as a trimer, which is consistent with the multimerization state of TNFα. Ia1-TNFα exhibited approximately 7-fold lower TNFα biological activity than that of TNFα itself. Flow cytometric analysis revealed that Ia1-TNFα specifically bound to EGFR-expressing tumor cells and that its binding activity was higher than that of monovalent Ia1, suggesting that the fusion protein bound to the tumor cells multivalently. Altogether, these results show that f...Continue Reading
References
Jan 1, 1992·Annual Review of Immunology·P Vassalli
Nov 8, 1985·Science·L J Old
Mar 1, 1996·Cytokine·W HolzerI von Hoegen
Oct 10, 1997·FEBS Letters·M Arbabi GhahroudiS Muyldermans
Nov 26, 1998·Cancer Immunology, Immunotherapy : CII·M HoffmannW Wels
Sep 27, 2000·International Journal of Cancer. Journal International Du Cancer·M G RosenblumL H Cheung
Feb 16, 2002·Protein Science : a Publication of the Protein Society·Mireille DumoulinAndre Matagne
Jun 26, 2002·Oncogene·Thomas WüestKlaus Pfizenmaier
Jan 14, 2003·Annual Review of Biochemistry·Hiroshi KadokuraJon Beckwith
Aug 23, 2003·Blood·Laura BorsiLuciano Zardi
Jan 7, 2004·Nature Reviews. Cancer·Glenn Dranoff
Mar 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stefan BauerChristoph Renner
Jan 13, 2005·The Journal of Biological Chemistry·Edwin BremerWijnand Helfrich
Jun 2, 2006·Cancer Immunology, Immunotherapy : CII·Rob C RooversPaul M P van Bergen en Henegouwen
Jun 25, 2009·Expert Opinion on Investigational Drugs·Brett H YamanePaul M Sondel
Aug 28, 2009·Journal of Biochemistry·Takuya ShishidoAkihiko Kondo
Sep 10, 2009·Clinical and Experimental Immunology·E MartinelliF Ciardiello
Mar 27, 2012·Archives of Biochemistry and Biophysics·Roland E Kontermann
Apr 13, 2012·Cell Death & Disease·M SiegemundK Pfizenmaier
Jun 8, 2012·Journal of Surgical Oncology·Francesco PapadiaFranco De Cian
Nov 20, 2012·Journal of Cancer Research and Clinical Oncology·G SpitaleriF de Braud
Jan 9, 2014·Nature Communications·Geneviève GarcinGilles Uzé
Sep 5, 2015·The FEBS Journal·Tomohiro OsakiTakeshi Nakanishi
Mar 16, 2017·Molecular Cancer Therapeutics·Ming-Hsien ChienMichael Hsiao